Evaluate treatment promptly for benefit/risk ratio of continuing if abnormal neurologic signs and symptoms develop. Severe hepatic impairment (Child-Pugh C): reduce metronidazole dose by 50%.

Evaluate treatment promptly for benefit/risk ratio of continuing if abnormal neurologic signs and symptoms develop. Severe hepatic impairment (Child-Pugh C): reduce metronidazole dose by 50%.

A prospective, randomized, controlled clinical trial compared metronidazole 250 mg orally four ... for patients to begin a lower-dosage regimen for CDAD treatment, increasing the dosage if the ...

With areas of practice changing rapidly, providers are challenged to keep abreast of new and changing treatment ... Metronidazole 500 mg orally twice a day for 14 days Regimen B Ceftriaxone 250 ...

the patients were treated with secnidazole (30 mg/kg single dose) and metronidazole (15 mg/kg tid for 7 days) randomly. Two weeks after the end of treatment, direct and formol- ether fecal ...